Arvinas (ARVN) Short-term Investments (2017 - 2026)
Arvinas' (ARVN) quarterly Short-term Investments came in at $527.6 million in Q1 2026, down 39.59% year-on-year from $873.3 million in Q1 2025, and down 2.75% quarter-over-quarter from $542.5 million in Q4 2025.
Arvinas (ARVN) Short-term Investments (2017 - 2026) Analysis & Trends
Arvinas' Short-term Investments history runs 10 years deep, the most recent figure standing at $527.6 million for Q1 2026.
- On a quarterly basis, Short-term Investments fell 39.59% year-over-year to $527.6 million in Q1 2026; TTM through Mar 2026 was $527.6 million, a 39.59% decrease from a year earlier, with the FY2025 full-year figure at $542.5 million, down 42.22% from the prior year.
- Short-term Investments slipped to $527.6 million in Q1 2026 per ARVN's latest filing, from $542.5 million in the prior quarter.
- Across five years, Short-term Investments topped out at $1.1 billion in Q1 2024 and bottomed at $4.5 million in Q1 2022.
- The 5-year median for Short-term Investments is $5.5 million (2022), against an average of $340.2 million.
- Across the five-year window, Short-term Investments slumped 99.57% in 2022 and surged 19560.0% in 2024, its largest moves.
- Year by year, Short-term Investments stood at $5.5 million in 2022, then changed by 0.0% to $5.5 million in 2023, then soared by 16970.91% to $938.9 million in 2024, then plunged by 42.22% to $542.5 million in 2025, then retreated by 2.75% to $527.6 million in 2026.
- Per Business Quant, the three latest ARVN Short-term Investments figures stand at $527.6 million (Q1 2026), $542.5 million (Q4 2025), and $686.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 527.60 Mn |
| Dec 31, 2025 | 542.50 Mn |
| Sep 30, 2025 | 686.10 Mn |
| Jun 30, 2025 | 746.30 Mn |
| Mar 31, 2025 | 873.30 Mn |
| Dec 31, 2024 | 938.90 Mn |
| Jun 30, 2024 | 5.50 Mn |
| Mar 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 5.50 Mn |
| Sep 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Mar 31, 2023 | 5.50 Mn |
| Dec 31, 2022 | 5.50 Mn |
| Sep 30, 2022 | 5.50 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 4.50 Mn |
| Dec 31, 2021 | 4.50 Mn |
| Sep 30, 2021 | 1.29 Bn |
| Jun 30, 2021 | 4.50 Mn |
| Mar 31, 2021 | 305.20 Mn |